2021 ACR/VF 巨细胞动脉炎与大动脉炎管理指南
该指南由美国风湿病学会(ACR)与血管炎基金会(VF)制定,针对巨细胞动脉炎(GCA)和大动脉炎(TAK)提出循证推荐与专家指导。指南基于PICO格式的临床问题、系统文献评价和GRADE方法,经投票小组≥70%共识形成推荐。GCA部分包括22条推荐和2条未分级立场声明,TAK部分包括20条推荐和1条未分级立场声明,涉及诊断检查(含影像)、治疗和手术干预。
要点
- GCA推荐支持使用减少糖皮质激素的免疫抑制剂及影像学识别大血管受累。
- TAK推荐初始治疗使用非糖皮质激素免疫抑制剂联合糖皮质激素。
- 仅2条推荐为强推荐,其余因证据质量低均为条件性推荐。
核心结论
- 指南为GCA和TAK的评估与管理提供循证推荐,涵盖诊断策略、药物使用和手术干预。
研究设计与样本
- 由ACR和VF制定,针对GCA和TAK分别提出27个PICO临床问题,进行系统文献评价,采用GRADE方法评级证据质量,由投票小组(成人及儿童风湿科医生和患者)以≥70%共识形成推荐。
主要发现
- GCA部分提出22条推荐和2条未分级立场声明,TAK部分提出20条推荐和1条未分级立场声明。
- GCA推荐包括支持使用减少糖皮质激素的免疫抑制剂和影像学识别大血管受累。
- TAK推荐包括初始治疗使用非糖皮质激素免疫抑制剂联合糖皮质激素。
- 仅2条推荐为强推荐,其余推荐因多数PICO问题证据质量低而为条件性推荐。
关键数值与推荐
- 每条推荐需投票小组≥70%共识。
- GCA推荐包括支持使用减少糖皮质激素的免疫抑制剂和影像学识别大血管受累。
- TAK推荐包括初始治疗使用非糖皮质激素免疫抑制剂联合糖皮质激素。
- 仅2条推荐为强推荐,其余为条件性推荐。
临床怎么用
- 临床可依据指南推荐对GCA和TAK进行诊断检查(含影像)、药物治疗和手术干预的决策。
- GCA患者可考虑减少糖皮质激素的免疫抑制剂和影像学评估大血管受累。
- TAK患者初始治疗可考虑非糖皮质激素免疫抑制剂联合糖皮质激素。
- 需注意多数推荐为条件性,应结合证据质量低的情况进行个体化决策。
局限性
- 多数PICO问题的现有证据质量低,导致仅2条推荐为强推荐,其余均为条件性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. METHODS: Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. CONCLUSION: These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
引用
- Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021. PMID: 34235884. doi:10.1002/art.41774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。